首页> 外文期刊>Clinical oncology >Trastuzumab-induced radiation recall dermatitis--first reported case.
【24h】

Trastuzumab-induced radiation recall dermatitis--first reported case.

机译:曲妥珠单抗引起的放射性召回性皮炎-首例报道。

获取原文
获取原文并翻译 | 示例
       

摘要

We would like to report the first case to our knowledge of radiation recall dermatitis (RRD) triggered by trastuzumab (Herceptin®). A 71-year-old woman with previous left mastectomy for ductal carcinoma in situ presented with distortion of her right breast in February 2008. Ultrasound-guided core biopsy confirmed invasive ductal carcinoma. She underwent right-sided mastectomy and axillary nodal dissection. Histopathology confirmed multifo-cal invasive breast cancer. Two tumours were identified: a grade 111, 35 mm, oestrogen receptor-positive, progesterone receptor-negative, Her2-positive invasive ductal cancer and a grade II, 35 mm, oestrogen receptor-positive, progesterone receptor-positive, Her2-negative, invasive lobular cancer. The ductal carcinoma was Her-2 (Herceptest) 2+ and fluorescence in situ hybridisation amplified. Four lymph nodes were positive for cancer out of 14 nodes examined.
机译:我们想向我们报告第一例由曲妥珠单抗(Herceptin®)引发的放射性召回性皮炎(RRD)的知识。一名先前因导管癌原位左乳房切除术的71岁妇女在2008年2月表现出右乳畸形。超声引导下的活检证实了浸润性导管癌。她接受了右侧乳房切除术和腋窝淋巴结清扫术。组织病理学证实为多灶性浸润性乳腺癌。确定了两个肿瘤:111级,35毫米,雌激素受体阳性,孕激素受体阴性,Her2阳性浸润性导管癌和II级,35毫米,雌激素受体阳性,孕激素受体阳性,Her2阴性,浸润性小叶癌。导管癌为Her-2(Herceptest)2+,荧光原位杂交得到扩增。在检查的14个淋巴结中,有4个淋巴结呈阳性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号